News
Pfizer’s first-quarter revenue missed analyst estimates as it faces an “uncertain and volatile external environment.” ...
Pfizer said on Tuesday it would generate $1.7 billion more in savings from cost cuts to its manufacturing and research ...
Big pharmaceutical companies as well as smaller biotechs have been hoping to score a win in one of today's highest-growth ...
A study published earlier this week in Nature Communications using claims data from the US Veterans Affairs (VA) Healthcare ...
The company expects to save an additional $1.2 billion from automation, AI and other digital tools.
The company disclosed revenue of $13.7 billion and adjusted earnings of $0.92 per share, compared to consensus estimates of ...
Pfizer and Arvinas have axed two phase 3 trials from their estrogen receptor (ER) degrader R&D plan in the wake of mixed data ...
Pfizer is raising the bar for its sweeping cost-savings drive yet again, this time cranking up the total target to $7.7 ...
Given the stock’s generous 7% yield, maybe junk bond investors should take a look.The venerable drug company, which also ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback